Fenofibrate tablets are used to manage high cholesterol and triglyceride levels in the blood. They are primarily prescribed for patients with hyperlipidemia, a condition characterized by elevated levels of lipids (fats) such as cholesterol and triglycerides.
What are the main uses for fenofibrate tablets?
Fenofibrate tablets are indicated for the treatment of adults with:
* Hypertriglyceridemia: Very high levels of triglycerides in the blood, which can increase the risk of pancreatitis.
* Mixed dyslipidemia: High levels of both triglycerides and low-density lipoprotein (LDL, or "bad") cholesterol, or low levels of high-density lipoprotein (HDL, or "good") cholesterol.
* Primary hypercholesterolemia (or mixed dyslipidemia): High levels of cholesterol, often in conjunction with other lipid abnormalities.
These medications work by reducing the production of certain fats in the liver and increasing the removal of fats from the blood [1].
How does fenofibrate help lower cholesterol and triglycerides?
Fenofibrate belongs to a class of drugs called fibrates. It works by activating peroxisome proliferator-activated receptors (PPARs) in the body, primarily PPAR-alpha. Activation of PPAR-alpha leads to several effects that lower lipid levels:
* It increases lipoprotein lipase activity, which helps break down triglycerides.
* It reduces the production of very-low-density lipoproteins (VLDL), a type of triglyceride-rich particle, by the liver.
* It increases the production of HDL cholesterol [2].
When do fenofibrate patents expire?
The patent expiration dates for fenofibrate vary depending on the specific formulation and market. For instance, some patents related to fenofibrate formulations may have expired, allowing for generic versions to be available. DrugPatentWatch.com tracks these patent statuses, which are crucial for understanding market exclusivity and the potential for generic competition [3].
Can generic fenofibrate be used?
Yes, generic versions of fenofibrate tablets are available. Once patents expire and regulatory approvals are obtained, other pharmaceutical companies can manufacture and market generic versions of the drug, typically at a lower cost than the brand-name product.
What are the risks or side effects of taking fenofibrate?
Like all medications, fenofibrate can cause side effects. Common side effects include gastrointestinal issues like nausea, stomach pain, and diarrhea. More serious side effects, though less common, can include:
* Muscle problems: Including muscle pain, tenderness, weakness, and in rare cases, rhabdomyolysis (severe muscle breakdown).
* Liver problems: Such as elevated liver enzymes, and in rare instances, liver damage or failure.
* Gallbladder problems: Increased risk of gallstones or gallbladder inflammation.
* Pancreatitis: Inflammation of the pancreas, particularly in patients with very high triglyceride levels.
It is important for patients to report any unusual symptoms to their healthcare provider [1].
How does fenofibrate compare to other cholesterol-lowering medications?
Fenofibrate is primarily used to lower triglycerides and raise HDL cholesterol, while statins are the first-line treatment for lowering LDL cholesterol. In cases of mixed dyslipidemia where both LDL and triglycerides are high, fenofibrate might be used in combination with a statin, or as an alternative if statins are not tolerated or effective enough for triglyceride reduction. However, combining fenofibrate with statins carries a higher risk of muscle-related side effects [1][4].
Who manufactures fenofibrate?
Brand-name fenofibrate is manufactured by various pharmaceutical companies. For example, Tricor was one of the original brand names. Numerous generic manufacturers also produce fenofibrate tablets.
What clinical data supports the use of fenofibrate?
Clinical trials have demonstrated fenofibrate's efficacy in reducing triglyceride and LDL cholesterol levels, and increasing HDL cholesterol. Studies have also investigated its role in preventing cardiovascular events, particularly in patients with diabetes and dyslipidemia, though results have sometimes been complex and subject to interpretation, especially when compared to statin therapy alone [1][5].